3	, אוטו						Page 1 of 1
Subst. Form	REGINA	KONT	Atty. Docket No.: 2	6473/04177		Serial N	o.: 10/039,753
APPLICAN DISCLOSU		INFORMATION TEMENT					
Dischool		I EMENT	Applicant: Hazen,	et al		ــــــــــــــــــــــــــــــــــــــ	
			Filing Date: January			Group:	3736
			1 ming Date: Vanianty	2, 2002		1 Oldapi	3730
			U.S. PATE	NT DOCUMENTS			
Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
PN	AA	6,268,220	July 31, 2001	Heinecke			Sep. 9, 1996
	AB						
•	AC						
	AD						
		Document No.	Date	Country	Class	Subcl.	Translation?
	AE	Document No.	Date	Country	Class	Subci.	Translation:
	AF					 	
	AG					 	-
	AH					 	
	AI	 	 			 	
	1 24	<u> </u>	I	<u>l</u>		1	
			ОТНЕ	R PRIOR ART		<u>-:</u>	
	AJ					37	刃
	AK)C	M
	AL						
	AM					1 6	m m
	AN					- 2	ΓÑ
	AO						0
	AP					()	
	AQ				-	9.	
	AR						
					,		

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner:



Date Considered: 3/19/04



RECEIVED

SEP 1 1 2002

Subst. Form I	TO-14	49	Atty. Docket No.: 264	73/04177			TER 1600/2
APPLICANT'S INFORMATION DISCLOSURE STATEMENT			•				·
			Applicant: Hazen, et	al.			
			Filing Date: January 2			Group: 3	736
			U.S. PATEN	T DOCUMENTS			·
Initial*		Document No.	Date	Name	Class	Subcl.	Filing Dat
PN	AA	5,122,534	June 16, 1992	Loose, et al.			Jul. 10, 19
PN	AB	5,889,042	March 30, 1999	MacLean, et al.			Feb. 21, 19
TPAT	AC					†	
2	ÁD		· · · · · · · · · · · · · · · · · · ·			1	
6 2 1 2002 &			FOREIGN PAT	ENT DOCUMENTS			
> ust 9		Document No.	Date	Country	Class	Subcl.	Translati
WAUE	AE_						
	AF						
	AG				HIE ()	一一一	
	AH					~0	
	AI				AUG 2	2002	
		•	OTHER	PRIOR ART TE	044010370	ENTER RETO	00
PN	AJ		ch Report dated July 31,				
PN	AK	"Oxidized LDL a	nd HDL: antagonists in a	therothrombosis" by Merten	s, et al., FAS	EB J., 15, 20	73-2084 (20
PN	AL	nitrogen species"	by Podrez, et al., J. Clin.	the major receptor for LDL in Ivest. 105:1095-1108 (2000)). `		
PN	AM	Dysfunction in D	ogs <i>in vivo</i> " by Momii, et	lly Ameliorates Cytokine-Indal., J. Mol. Cell. Cardiol. 30), 2637-2650	(1998).	
PN	AN			Suppresses the Development tension, 2001; 38:1044-1048		sion in Spon	taneously
	AO						
·	AP						
	AQ						
	AR						
	لـما	L					
Examiner:		ger Nor		Date Considered	: 3/19	/ar	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

E E	OT F	-	~	COPY OF PAPERS ORIGINALLY FILED	RECE	<i>1</i>)		Page 1 of 1
Ø.	Subst. Forbi	PTO-14	49	Atty. Docket No.: 26473/0	14177 4112	ED	Serial No	o.: 10/039,753
	Subst. Forth I RADEMA	'S I E STA?	NFORMATION FEMENT		RECE 14177 AUG 1 4 2 TECHNOLOGY CENTE	1002		
				Applicant: Hazen, et al.	UENTE	8,7		,
				Filing Date: January 2, 200	02	10700	Group:	
	-			U.S. PATENT D	OCUMENTS .			Z → III
	Initial*		Document No.	Date	Name	Class	Subcl.	Filim Dace
		AA					<u> </u>	20
		AB						<u> </u>
		AC AD					<u> </u>	<u>§</u> 6
		, AD	1	FOREIGN PATENT	r documents		600/2900	" "
			Document No.	Date	Country	Class	Subcl.	Translation?
		AE						
		AF					<u> </u>	<u> </u>
		AG						<u> </u>
		AH					 	
		AI	<u> </u>	<u> </u>			L	<u> </u>

OTHER PRIOR ART

PN	AJ	"Myeloperoxidase Deficiency" by Nauseef, <u>Hematology, Oncology Clinics of North America</u> , Vol. 2, No.1, March 1988, pp. 135-158.					
	AK	"Primary Inherited Defects in Neutrophil Function: Etiology and Treatment" by Malech, et al., <u>Seminars</u> in <u>Hematology</u> , Vol. 34, No. 4, October, 1997, pp. 279-290.					
	AL	"Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall" by Heinecke, et al., <u>FASEB J.</u> , 13, 1113-1120 (1999).					
	AM	"Myeloperoxidase-Generated Oxidants and Atherosclerosis" by Podrez, et al., Free Radical Biology & Medicine, Vol. 28, No. 12, pp. 1717-1725, January, 2000.					
	AN	"Myeloperoxidase, a Catalyst for Lipoprotein Oxidation, Is Expressed in Human Atherosclerosis Lesions by Daugherty, et al., J. Clin. Invest., Vol. 94, July 1994, 437-444.					
	AO	"3-Chlorotyrosine, a Specific Marker of Myeloperoxidase-catalyzed Oxidation, Is Markedly Elevated in Low Density Lipoprotein Isolated from Human Atherosclerosis Intima" by Hazen, et al., <u>J. Clin. Invest.</u> , Vol. 99, No. 9, May, 1997, 2075-2081.					
	AP	"Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino acid-derived aldehyde generated by myeloperoxidase, are present in hun fatty streaks, intermediate lesions and advanced atherosclerosis lesions' by Hazen, et al., Biochem J. (2000) 352, 693-699.					
PN	AQ	"p-Hydroxypheylacetaldehyde, an Aldehyde Generated by Myeloperoxidase, Modifies Phospholipid Amino Groups of Low Density Lipoprotein in Human Atherosclerosis Intima" by Heller, et al., <u>The Journal of Biological Chemistry</u> , Vol. 275, No. 14, April 7, 2000, pp. 9957-9962.					
	AR						
aminer:	Pax.	Date Considered: 3/19/15					

^{*}EXAMINER: Initial if reference c nsidered, whether or not citation is in conf rmation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

Page	1	۸f	1
T 4EC		UL	J

\ 7 }		· · · · · · · · · · · · · · · · · · ·
Subst. Form PTO-1449	Atty. Docket No.: 26473/04177	Serial No.: 10/039,753
APPLICANT'S INFORMATION DISCLOSURE STATEMENT		·
	Applicant: Hazen, et al.	
	Filing Date: January 2, 2002	Group: 3736
	U.S. PATENT DOCUMENTS	
		Clara Cabal Filing Date

Initial*		Document No.	Date	Name BE	Class	Subcl.	Filing Date
	AA			nec	EIVE		
	AB						<u> </u>
	AC			AUG -	7 2002		
	AD			Train			<u></u>
			FOREIGN	PATENT DOCUMENTS	ENTER R3	700	

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
A	Æ						
A	F			`			
A	G						
A	ΙΗ					<u></u>	<u> </u>
	I					<u> </u>	<u> </u>

OTHER PRIOR ART

PN	AJ	"Association Between Myeloperoxidase Levels and Risk of Coronary Artery Disease" by Zhang, et al., <u>JAMA</u> , Vol. 286, No. 17, November 7, 2001, pp. 2136-2142.
PN	AK	"Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis? Do the Antioxidant Trials Conducted to Date Refute the Hypothesis?" by Steinberg, et al., Circulation, 2002; 105:2107-2111.
	AL	
	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
Examiner:	fat	¬ √√√ Date Considered: 5//9/Ø

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

Subst. Form PTO-1449	Atty. Docket No.: 26473/04177	Serial No.: 10/039,753
APPLICANT'S INFORMATION DISCLOSURE STATEMENT	· 	
	Applicant: Hazen, et al.	
	Filing Date: January 2, 2002	Group: 3736

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
	AA						
	AB						
	AC						
	. AD						

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
PNI	AE	0 389 381	September 26, 1990	EP			
PN	AF	02/50550	June 27, 2002	WO	-,		
	AG					L	
	AH						
	AI						

OTHER PRIOR ART

	AJ	Supplementary European Search Report dated January 29, 2004.
PP	AK	"Kinetics of Oxidation of Tyrosine and Dityrosine by Myeloperoxidase Compounds I and II" by Marquez, et al., The Journal of Biological Chemistry, Vol. 270, No. 51, December 22, 1995, pp. 30434-30440.
PN	AL	"Leukocytes Utilize Myeloperoxidase-Generated Nitrating Intermediates as Physiological Catalysts for the Generation of Biologically Active Oxidized Lipids and Sterols in Serum" by Schmitt, et al., <u>Biochemistry</u> , 1999, 38, 16904-16915.
PN	AM	"Nitric Oxide Modulates the Catalytic Activity of Myeloperoxidase" by Abu-Soud, et al., The Journal of Biological Chemistry, Vol. 275, No. 8, February 25, 2000, pp. 5425-5430.
	AN	·
	AO	
	AP	
	AQ	
	AR	
	0	
Examiner:	Patr	Date Considered: 3/19/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.